Proton pump inhibitor prescription abuse and sepsis in cirrhosis
- PMID: 26855807
- PMCID: PMC4734942
- DOI: 10.4292/wjgpt.v7.i1.1
Proton pump inhibitor prescription abuse and sepsis in cirrhosis
Abstract
Proton pump inhibitors (PPIs) represent one of the most extensively prescribed classes of drugs in general and in patients with liver cirrhosis. Many prescriptions are made without a clear adherence to standard indications. As a class of ordinarily well tolerated drug, PPIs are not free of side-effects and concerns have been raised about a possible role for PPIs in predisposing patients to an increased risk of bacterial infections and sepsis. As evidences of different power are accumulating on this topic, prospective studies are needed to reach a more universal agreement, but definitely more attention is needed by prescribers in being more adherent to the few recognized indications for the use of PPIs, particularly in patients with liver cirrhosis. Otherwise, doctors could run the risk of being accused of "abused" prescription.
Keywords: Bacterial infection; Liver cirrhosis; Proton pump inhibitors; Sepsis.
Similar articles
-
Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites.Ann Pharmacother. 2012 Oct;46(10):1413-8. doi: 10.1345/aph.1R174. Epub 2012 Oct 2. Ann Pharmacother. 2012. PMID: 23032651 Review.
-
Use of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosis.J Gastroenterol Hepatol. 2015 Jan;30(1):147-54. doi: 10.1111/jgh.12667. J Gastroenterol Hepatol. 2015. PMID: 25039465
-
Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards.Eur J Gastroenterol Hepatol. 2008 Jul;20(7):608-12. doi: 10.1097/MEG.0b013e3282f52f95. Eur J Gastroenterol Hepatol. 2008. PMID: 18679061
-
[Validity of proton pump inhibitors' prescriptions in a department of internal medicine].Rev Med Interne. 2007 Feb;28(2):86-93. doi: 10.1016/j.revmed.2006.09.030. Epub 2006 Oct 20. Rev Med Interne. 2007. PMID: 17092611 French.
-
The risks of long-term use of proton pump inhibitors: a critical review.Ther Adv Drug Saf. 2018 Nov 19;10:2042098618809927. doi: 10.1177/2042098618809927. eCollection 2019. Ther Adv Drug Saf. 2018. PMID: 31019676 Free PMC article. Review.
Cited by
-
The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis.Dis Markers. 2022 Jun 28;2022:4093595. doi: 10.1155/2022/4093595. eCollection 2022. Dis Markers. 2022. PMID: 35801003 Free PMC article.
-
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Clin Drug Investig. 2017 Jul;37(7):587-624. doi: 10.1007/s40261-017-0519-y. Clin Drug Investig. 2017. PMID: 28361440 Review.
-
Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.Sci Rep. 2019 Aug 19;9(1):12000. doi: 10.1038/s41598-019-48352-5. Sci Rep. 2019. PMID: 31427714 Free PMC article.
References
-
- Pezzulo G, Kruger D. Assessing upper gastrointestinal bleeding in adults. JAAPA. 2014;27:19–25. - PubMed
-
- Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–659. - PubMed
-
- Cheng DW, Lu YW, Teller T, Sekhon HK, Wu BU. A modified Glasgow Blatchford Score improves risk stratification in upper gastrointestinal bleed: a prospective comparison of scoring systems. Aliment Pharmacol Ther. 2012;36:782–789. - PubMed
-
- Holland-Bill L, Christiansen CF, Gammelager H, Mortensen RN, Pedersen L, Sørensen HT. Chronic liver disease and 90-day mortality in 21,359 patients following peptic ulcer bleeding--a Nationwide Cohort Study. Aliment Pharmacol Ther. 2015;41:564–572. - PubMed
-
- Holt S, Howden CW. Omeprazole. Overview and opinion. Dig Dis Sci. 1991;36:385–393. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials